As a result, we have successfully developed what is, to the best of our knowledge, the first mouse melanoma model with preserved in vivo expression of human EGFR, suitable for in vivo efficacy studies of EGFR-targeted drugs in syngeneic transplantable melanoma tumor setting. This evidence concerns the gene EGFR and neoplasm.